{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:14:20Z","timestamp":1789708460425,"version":"4.0.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jccjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Critical Care"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.jcrc.2015.01.022","type":"journal-article","created":{"date-parts":[[2015,2,7]],"date-time":"2015-02-07T17:16:11Z","timestamp":1423329371000},"page":"652.e9-652.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Intravenous immunoglobulin in critically ill adults: When and what is the evidence?"],"prefix":"10.1016","volume":"30","author":[{"given":"J.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.K.","family":"McQuilten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Aubron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jcrc.2015.01.022_bb0005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-3148.2010.01022.x","article-title":"Use of intravenous immune globulin in the ICU: a retrospective review of prescribing practices and patient outcomes","volume":"20","author":"Foster","year":"2010","journal-title":"Transfus Med"},{"key":"10.1016\/j.jcrc.2015.01.022_bb0010","series-title":"Criteria for the clinical use of intravenous immunoglobulin in Australia","author":"National IVIg Criteria Review Working Group","year":"2012"},{"issue":"2","key":"10.1016\/j.jcrc.2015.01.022_bb0015","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.tmrv.2007.01.002","article-title":"Guidelines on the use of intravenous immune globulin for neurologic conditions","volume":"21","author":"Feasby","year":"2007","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.jcrc.2015.01.022_bb0025","first-page":"57","article-title":"Trends in drug use in intensive care units in Japan: determinants of drug utilization under an evidence-based approach to medicine","volume":"27","author":"Sugiura","year":"2008","journal-title":"Jpn Hosp"},{"issue":"1","key":"10.1016\/j.jcrc.2015.01.022_bb0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1423-0410.2009.01226.x","article-title":"Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance","volume":"98","author":"Radosevich","year":"2010","journal-title":"Vox Sang"},{"issue":"4","key":"10.1016\/j.jcrc.2015.01.022_bb0035","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.intimp.2005.11.005","article-title":"IGIV: contents, properties, and methods of industrial production\u2014evolving closer to a more physiologic product","volume":"6","author":"Martin","year":"2006","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.jcrc.2015.01.022_bb0040","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jpeds.2005.08.024","article-title":"Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin","volume":"148","author":"Tsai","year":"2006","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.jcrc.2015.01.022_bb0045","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2340\/00015555-0900","article-title":"Not all intravenous immunoglobulin preparations are equally well tolerated","volume":"90","author":"Feldmeyer","year":"2010","journal-title":"Acta Derm Venereol"},{"issue":"11P2","key":"10.1016\/j.jcrc.2015.01.022_bb0055","doi-asserted-by":"crossref","first-page":"85S","DOI":"10.1592\/phco.2005.25.11part2.85S","article-title":"The patient: emerging clinical applications of intravenous immunoglobulin","volume":"25","author":"Harvey","year":"2005","journal-title":"Pharmacother"},{"issue":"21","key":"10.1016\/j.jcrc.2015.01.022_bb0060","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcrc.2015.01.022_bb0065","first-page":"22","article-title":"Rates of increases for IVIg use in NSW and Australia","volume":"41","author":"Wood","year":"2011","journal-title":"Intern Med J"},{"issue":"6","key":"10.1016\/j.jcrc.2015.01.022_bb0070","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00228-010-0800-y","article-title":"Use of non-specific intravenous human immunoglobulins in Spanish hospitals; need for a hospital protocol","volume":"66","author":"Ruiz-Antor\u00e1n","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jcrc.2015.01.022_bb0075","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1472-8206.2010.00908.x","article-title":"Use of intravenous immunoglobulins in clinical practice: data from three French university hospitals","volume":"25","author":"Frauger","year":"2011","journal-title":"Fundam Clin Pharmacol"},{"issue":"17","key":"10.1016\/j.jcrc.2015.01.022_bb0080","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome","volume":"326","author":"Van der Meche","year":"1992","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcrc.2015.01.022_bb0280","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1212\/WNL.46.1.100","article-title":"Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome","volume":"46","author":"Bril","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jcrc.2015.01.022_bb0090","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome","volume":"349","author":"Hughes","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jcrc.2015.01.022_bb0285","doi-asserted-by":"crossref","DOI":"10.11604\/pamj.2014.18.35.2911","article-title":"Intravenous immunoglobulin vs plasma exchange in treatment of mechanically ventilated adults with Guillain-Barr\u00e9 syndrome","volume":"18","author":"Charra","year":"2014","journal-title":"Pan Afr Med J"},{"key":"10.1016\/j.jcrc.2015.01.022_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002063.pub6","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","volume":"9","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.jcrc.2015.01.022_bb0105","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1016\/j.jcrc.2015.01.022_bb0100","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"issue":"23","key":"10.1016\/j.jcrc.2015.01.022_bb0110","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jcrc.2015.01.022_bb0115","first-page":"CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"Gajdos","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.jcrc.2015.01.022_bb0120","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","article-title":"Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome","volume":"47","author":"Bain","year":"1996","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jcrc.2015.01.022_bb0290","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/(SICI)1097-4598(199705)20:5<614::AID-MUS13>3.0.CO;2-W","article-title":"Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin","volume":"20","author":"Rich","year":"1997","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.jcrc.2015.01.022_bb0295","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/(SICI)1097-4598(199706)20:6<674::AID-MUS3>3.0.CO;2-5","article-title":"Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin","volume":"20","author":"Muchnik","year":"1997","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.jcrc.2015.01.022_bb0300","first-page":"682","article-title":"Use of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome","volume":"102","author":"Peterlin","year":"2002","journal-title":"J Am Osteopath Assoc"},{"key":"10.1016\/j.jcrc.2015.01.022_bb0125","first-page":"CD003279","article-title":"Treatment for Lambert-Eaton myasthenic syndrome","volume":"2","author":"Keogh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"27","key":"10.1016\/j.jcrc.2015.01.022_bb0135","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcrc.2015.01.022_bb0305","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jcrc.2015.01.022_bb0310","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","article-title":"High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study","volume":"247","author":"Walter","year":"2000","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.jcrc.2015.01.022_bb0315","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/s10165-011-0534-4","article-title":"Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial","volume":"22","author":"Miyasaka","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"5","key":"10.1016\/j.jcrc.2015.01.022_bb0320","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10067-012-1940-5","article-title":"Intravenous immunoglobulin therapy in adult patients with polymyositis\/dermatomyositis: a systematic literature review","volume":"31","author":"Wang","year":"2012","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.jcrc.2015.01.022_bb0325","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/clinids\/21.6.1469","article-title":"Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal infections: case report and review","volume":"21","author":"Lamothe","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jcrc.2015.01.022_bb0330","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1592\/phco.19.13.1094.31589","article-title":"Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis: case report and review","volume":"19","author":"Cawley","year":"1999","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"issue":"2","key":"10.1016\/j.jcrc.2015.01.022_bb0200","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jamcollsurg.2008.10.032","article-title":"Necrotizing fasciitis: current concepts and review of the literature","volume":"208","author":"Sarani","year":"2009","journal-title":"J Am Coll Surg"},{"issue":"3","key":"10.1016\/j.jcrc.2015.01.022_bb0230","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1086\/376630","article-title":"Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial","volume":"37","author":"Darenberg","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jcrc.2015.01.022_bb0225","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/515199","article-title":"Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome\u2014a comparative observational study","volume":"28","author":"Kaul","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jcrc.2015.01.022_bb0335","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/cid\/ciu449","article-title":"Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study","volume":"59","author":"Linn\u00e9r","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jcrc.2015.01.022_bb0340","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J Burn Care Rehabil"},{"issue":"6","key":"10.1016\/j.jcrc.2015.01.022_bb0215","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1097\/BCR.0b013e318254d2ec","article-title":"Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China","volume":"33","author":"Zhu","year":"2012","journal-title":"J Burn Care Res"},{"issue":"2","key":"10.1016\/j.jcrc.2015.01.022_bb0210","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","article-title":"The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"167","author":"Huang","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jcrc.2015.01.022_bb0345","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-510X(99)00072-6","article-title":"Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis","volume":"165","author":"Pradhan","year":"1999","journal-title":"J Neurol Sci"},{"issue":"6","key":"10.1016\/j.jcrc.2015.01.022_bb0350","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1212\/WNL.54.6.1370","article-title":"Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin","volume":"54","author":"Sahlas","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jcrc.2015.01.022_bb0355","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/PL00007836","article-title":"Effectiveness of intravenous immunoglobulin treatment in adult patients with steroid-resistant monophasic or recurrent acute disseminated encephalomyelitis","volume":"249","author":"Marchioni","year":"2002","journal-title":"J Neurol"},{"issue":"3\u20134","key":"10.1016\/j.jcrc.2015.01.022_bb0360","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.neures.2012.09.006","article-title":"Refractory acute disseminated encephalomyelitis with anti-galactocerebroside antibody","volume":"74","author":"Samukawa","year":"2012","journal-title":"Neurosci Res"},{"issue":"1","key":"10.1016\/j.jcrc.2015.01.022_bb0365","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00007890-200101150-00009","article-title":"A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection","volume":"71","author":"Casadei","year":"2001","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.jcrc.2015.01.022_bb0370","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00007890-200108150-00010","article-title":"Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients","volume":"72","author":"Luke","year":"2001","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.jcrc.2015.01.022_bb0375","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1744-9987.2009.00664.x","article-title":"Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience","volume":"13","author":"Slatinska","year":"2009","journal-title":"Ther Apher Dial"},{"issue":"5","key":"10.1016\/j.jcrc.2015.01.022_bb0380","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/01.TP.0000128194.55934.48","article-title":"Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection","volume":"78","author":"White","year":"2004","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.jcrc.2015.01.022_bb0385","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1365-2141.1994.tb05000.x","article-title":"High-dose gamma-globulin therapy in the reactive haemophagocytic syndrome","volume":"88","author":"Gill","year":"1994","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.jcrc.2015.01.022_bb0390","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.ejim.2011.07.010","article-title":"Favourable outcome of life-threatening infectious-related haemophagocytic syndrome after combination treatment with corticosteroids and intravenous immunoglobulin infusions","volume":"22","author":"Argyraki","year":"2011","journal-title":"Eur J Intern Med"},{"issue":"5","key":"10.1016\/j.jcrc.2015.01.022_bb0395","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/ckj\/sft077","article-title":"Rejection-triggered haemophagocytic syndrome in renal transplantation successfully treated with intravenous immunoglobulin","volume":"6","author":"Marques","year":"2013","journal-title":"Clin Kidney J"},{"issue":"21\u201322","key":"10.1016\/j.jcrc.2015.01.022_bb0400","first-page":"299","article-title":"Haemophagocytic syndromes in adults: current concepts and challenges ahead","volume":"135","author":"Emmenegger","year":"2005","journal-title":"Swiss Med Wkly"},{"issue":"7","key":"10.1016\/j.jcrc.2015.01.022_bb0405","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"QJM"},{"issue":"12","key":"10.1016\/j.jcrc.2015.01.022_bb0410","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1136\/ard.2003.015453","article-title":"Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome","volume":"63","author":"Danieli","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jcrc.2015.01.022_bb0415","first-page":"Cd007057","article-title":"Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis","volume":"1","author":"Fortin","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"2\u20133","key":"10.1016\/j.jcrc.2015.01.022_bb0185","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12016-008-8107-9","article-title":"Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse","volume":"36","author":"Bucciarelli","year":"2009","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.jcrc.2015.01.022_bb0420","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1001\/archsurg.1991.01410260126018","article-title":"Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater","volume":"126","author":"Dominioni","year":"1991","journal-title":"Arch Surg (Chicago, Ill: 1960)"},{"issue":"9","key":"10.1016\/j.jcrc.2015.01.022_bb0425","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/00003246-199109000-00003","article-title":"Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial","volume":"19","author":"Schedel","year":"1991","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcrc.2015.01.022_bb0430","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/cc1523","article-title":"The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]","volume":"6","author":"Tugrul","year":"2002","journal-title":"Crit Care (Lond, Engl)"},{"issue":"4","key":"10.1016\/j.jcrc.2015.01.022_bb0435","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/01.shk.0000157302.69125.f8","article-title":"Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery","volume":"23","author":"Rodriguez","year":"2005","journal-title":"Shock"},{"issue":"12","key":"10.1016\/j.jcrc.2015.01.022_bb0440","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1097\/01.CCM.0000295426.37471.79","article-title":"Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study*","volume":"35","author":"Werdan","year":"2007","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcrc.2015.01.022_bb0445","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/j.jvca.2005.05.003","article-title":"Clinical experience with polyclonal IgM-enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery","volume":"19","author":"Buda","year":"2005","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"12","key":"10.1016\/j.jcrc.2015.01.022_bb0245","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1007\/s00134-014-3474-6","article-title":"Early therapy with IgM-enriched polyclonal immunoglobulin in patients with septic shock","volume":"40","author":"Cavazzuti","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jcrc.2015.01.022_bb0240","first-page":"CD001090","article-title":"Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock","volume":"9","author":"Alejandria","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.jcrc.2015.01.022_bb0450","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ajic.2006.06.007","article-title":"Clinical outcomes of intravenous immune globulin in severe Clostridium difficile\u2013associated diarrhea","volume":"35","author":"Juang","year":"2007","journal-title":"Am J Infect Control"},{"issue":"6","key":"10.1016\/j.jcrc.2015.01.022_bb0455","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1086\/660203","article-title":"An evaluation of the impact of a single-dose intravenous immunoglobulin regimen in the treatment of Clostridium difficile infections","volume":"32","author":"Aldeyab","year":"2011","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"10.1016\/j.jcrc.2015.01.022_bb0460","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/jhm.542","article-title":"Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature","volume":"5","author":"Abougergi","year":"2010","journal-title":"J Hosp Med"},{"issue":"5","key":"10.1016\/j.jcrc.2015.01.022_bb0465","doi-asserted-by":"crossref","DOI":"10.1186\/cc13028","article-title":"Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and\/or myopathy in patients with multiple organ failure and SIRS\/sepsis: a prospective, randomized, placebo-controlled, double-blinded trial","volume":"17","author":"Brunner","year":"2013","journal-title":"Crit Care"},{"issue":"11","key":"10.1016\/j.jcrc.2015.01.022_bb0470","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s001340050471","article-title":"Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis","volume":"23","author":"Mohr","year":"1997","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1016\/j.jcrc.2015.01.022_bb0475","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ajh.2830410305","article-title":"Inefficacy of intravenous immunoglobulin in patients with low-risk thrombotic thrombocytopenic purpura\/hemolytic-uremic syndrome","volume":"41","author":"Finazzi","year":"1992","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.jcrc.2015.01.022_bb0480","first-page":"253","article-title":"Hemolytic uremic syndrome\/thrombotic thrombocytopenic purpura (HUS\/TTP) complicating adult Still's disease: remission induced with intravenous immunoglobulin g","volume":"10","author":"Diamond","year":"1997","journal-title":"J Nephrol"},{"issue":"5","key":"10.1016\/j.jcrc.2015.01.022_bb0485","first-page":"733","article-title":"Hemolytic uremic syndrome after multivisceral transplantation treated with intravenous immunoglobulin","volume":"16","author":"Banerjee","year":"2003","journal-title":"J Nephrol"},{"issue":"4","key":"10.1016\/j.jcrc.2015.01.022_bb0490","first-page":"586","article-title":"Successful treatment of hemolytic uremic syndrome after liver-kidney transplantation","volume":"16","author":"Gatti","year":"2003","journal-title":"J Nephrol"},{"issue":"1","key":"10.1016\/j.jcrc.2015.01.022_bb0495","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5414\/CNP66058","article-title":"Rescue treatment for cyclosporine-associated hemolytic-uremic syndrome with intravenous immunoglobulin","volume":"66","author":"Wen","year":"2006","journal-title":"Clin Nephrol"},{"issue":"10","key":"10.1016\/j.jcrc.2015.01.022_bb0095","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1517\/14656566.2011.564160","article-title":"The role of immunotherapy in Guillain-Barr\u00e9 syndrome: understanding the mechanism of action","volume":"12","author":"Shahrizaila","year":"2011","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.jcrc.2015.01.022_bb0130","doi-asserted-by":"crossref","first-page":"i14","DOI":"10.1007\/s00415-005-1104-5","article-title":"IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status","volume":"252","author":"Illa","year":"2005","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.jcrc.2015.01.022_bb0140","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/BOR.0b013e32834ba787","article-title":"Clinical trials roundup in idiopathic inflammatory myopathies","volume":"23","author":"Mann","year":"2011","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.jcrc.2015.01.022_bb0145","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1378\/chest.10-0360","article-title":"Polymyositis associated with severe interstitial lung disease remission after three doses of IV immunoglobulin","volume":"139","author":"Bakewell","year":"2011","journal-title":"Chest"},{"issue":"2 Suppl 1","key":"10.1016\/j.jcrc.2015.01.022_bb0150","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.tmrv.2007.01.001","article-title":"Guidelines on the use of intravenous immune globulin for hematologic conditions","volume":"21","author":"Anderson","year":"2007","journal-title":"Transfus Med Rev"},{"issue":"Suppl. 1","key":"10.1016\/j.jcrc.2015.01.022_bb0155","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.tmrv.2009.09.010","article-title":"The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline","volume":"24","author":"Shehata","year":"2010","journal-title":"Transfus Med Rev"},{"issue":"2","key":"10.1016\/j.jcrc.2015.01.022_bb0160","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/bjh.12869","article-title":"Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study","volume":"166","author":"Frederiksen","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jcrc.2015.01.022_bb0165","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0042-9007.2004.00391.x","article-title":"Intravenous immunoglobulin and autoimmune thrombocytopenic purpura: 22 years on","volume":"86","author":"Bierling","year":"2004","journal-title":"Vox Sang"},{"issue":"2","key":"10.1016\/j.jcrc.2015.01.022_bb0170","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"issue":"9300","key":"10.1016\/j.jcrc.2015.01.022_bb0175","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(02)07275-6","article-title":"Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial","volume":"359","author":"Godeau","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jcrc.2015.01.022_bb0190","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1517\/14712598.6.2.155","article-title":"Therapies for necrotising fasciitis","volume":"6","author":"Young","year":"2006","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"10.1016\/j.jcrc.2015.01.022_bb0195","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jcrc.2004.04.001","article-title":"Intravenous immunoglobulin for severe infections: a survey of Canadian specialists","volume":"19","author":"Laupland","year":"2004","journal-title":"J Crit Care"},{"issue":"1","key":"10.1016\/j.jcrc.2015.01.022_bb0205","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Harr","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.jcrc.2015.01.022_bb0220","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1086\/606049","article-title":"Assessing the impact of intravenous immunoglobulin in the management of streptococcal toxic shock syndrome: a noble but difficult quest","volume":"49","author":"Valiquette","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jcrc.2015.01.022_bb0180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.autrev.2006.06.009","article-title":"Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry","volume":"6","author":"Cervera","year":"2006","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.jcrc.2015.01.022_bb0235","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/cc10597","article-title":"Bench-to-bedside review: immunoglobulin therapy for sepsis\u2014biological plausibility from a critical care perspective","volume":"16","author":"Shankar-Hari","year":"2012","journal-title":"Crit Care (Lond, Engl)"},{"issue":"6","key":"10.1016\/j.jcrc.2015.01.022_bb0250","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1186\/s13054-014-0649-z","article-title":"Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost effectiveness and value of a further randomised controlled trial","volume":"18","author":"Soares","year":"2014","journal-title":"Crit Care"},{"issue":"10","key":"10.1016\/j.jcrc.2015.01.022_bb0255","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1345\/aph.1K198","article-title":"Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid","volume":"41","author":"G\u00fcrcan","year":"2007","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.jcrc.2015.01.022_bb0260","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","article-title":"Safety of intravenous immunoglobulin (IVIG) therapy","volume":"6","author":"Katz","year":"2007","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.jcrc.2015.01.022_bb0265","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.thromres.2014.03.046","article-title":"Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study","volume":"133","author":"Ram\u00edrez","year":"2014","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.jcrc.2015.01.022_bb0270","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/CPJ.0b013e3182a78ecf","article-title":"Intravenous immunoglobulin for treatment of neuromuscular disease","volume":"3","author":"Ruzhansky","year":"2013","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.jcrc.2015.01.022_bb0275","series-title":"Intragram P Product Information [Internet]","author":"CSL Limited","year":"2014"}],"container-title":["Journal of Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944115000593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944115000593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T11:28:54Z","timestamp":1537874934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0883944115000593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0883944115000593"],"URL":"https:\/\/doi.org\/10.1016\/j.jcrc.2015.01.022","relation":{},"ISSN":["0883-9441"],"issn-type":[{"value":"0883-9441","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous immunoglobulin in critically ill adults: When and what is the evidence?","name":"articletitle","label":"Article Title"},{"value":"Journal of Critical Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcrc.2015.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}